News

Public · Published

Genmab says head and neck cancer drug cuts death risk by 50% with Merck's Keytruda

Genmab said its drug petosemtamab, given with Merck's Keytruda, cut the risk of death by 50% in certain head and neck cancer patients in a Phase 3 trial. The company plans to share full results with regulators.

Published:

Updated:

What happened

Genmab said its drug petosemtamab, given with Merck's Keytruda, cut the risk of death by 50% in certain head and neck cancer patients in a Phase 3 trial. The company plans to share full results with regulators.

Confirmed

Global impact / market context

A 50% lower risk of death, if confirmed by regulators, could make this combination a new first-choice treatment, which means more revenue for Genmab and Merck and a setback for rivals like Bicara developing similar drugs.

Analyst inference

The opposite share moves show investors see this as a competitive win for Genmab and Merck. Bicara's fall suggests its own Keytruda-based head and neck cancer program may now face a tougher path to standing out.

Analyst inference

What to watch

  1. Genmab plans to present full trial results at a future medical event and share them with global regulatory authorities, which means a filing review could follow. Confirmed
  2. Watch whether regulators accept the Phase 3 data for review and whether the 50% death-risk reduction holds across patient subgroups once full results are presented. Proposed
  3. Track Bicara's response, since a sharp share drop may reflect investor worry that its rival therapy will struggle to show similar survival benefits. Analyst inference

Evidence